Oragenics, Inc. Announces A Second Phase 1 Clinical Trial Of SMaRT™ Replacement Therapy
Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy. The Company has … more